Calcimedica announces presentation of initial data from the crspa study of auxora at the 65th annual ash meeting & exposition

Auxora ™  showed a 53% reduction in days in hospital, a 40% reduction in intensive care unit (icu) days and eliminated the need for total parenteral nutrition (tpn) la jolla, calif. , nov. 2, 2023 /prnewswire/ -- calcimedica inc. ("calcimedica") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced that there will be a presentation of data from the initial cohort of the crspa study of auxora™ (zegocractin) in asparaginase-induced pancreatic toxicity (aipt) in a poster presentation at the 65th annual american society of hematology (ash) meeting & exposition being held december 9-12, 2023 in san diego, ca.
CALC Ratings Summary
CALC Quant Ranking